Diabetes future

Quote
Bottom line is this. Our diabetic products lack a type of luster that requires such a large sales crew. Lets face it, we have small territories....a commodity (at best....insulin) to sell and talk about. We simply don't need the current quantity of reps to drop samples, and get a signature. And of course....our DPP4. I won't even comment on that. We made a big mistake turning our back on Amylin. Boys and girls.....we are in trouble. Hide your head in denial at your own peril.
 






Anonymous said:
Bottom line is this. Our diabetic products lack a type of luster that requires such a large sales crew. Lets face it, we have small territories....a commodity (at best....insulin) to sell and talk about. We simply don't need the current quantity of reps to drop samples, and get a signature. And of course....our DPP4. I won't even comment on that. We made a big mistake turning our back on Amylin. Boys and girls.....we are in trouble. Hide your head in denial at your own peril.
Click to expand...

But Enrique says we will be fine if we just maintain our fukus!
 






Anonymous said:
Bottom line is this. Our diabetic products lack a type of luster that requires such a large sales crew. Lets face it, we have small territories....a commodity (at best....insulin) to sell and talk about. We simply don't need the current quantity of reps to drop samples, and get a signature. And of course....our DPP4. I won't even comment on that. We made a big mistake turning our back on Amylin. Boys and girls.....we are in trouble. Hide your head in denial at your own peril.
Click to expand...

There's a lot of truth to what you say. In fact, you could equate a lot more companies in the same boat.
 






Anonymous said:
The problem with Lilly is that they never want to do a competitive bid such that they would have an NDC lock on Novo insulins. This applies to National and ESPECIALLY Regional formularies. Their company. Ever gets caught with promoting off-label and they give the customer what they ask for..... They are not under any CIA agreement, they promote very well in the hospital and LTC market where Lilly SUCKS and last but not least they out rep us 4 to 1!!!
Click to expand...

Hello?

Novo is under CIA since May of 2011! So why use CIA as any excuse.....
 






Anonymous said:
Hello?

Novo is under CIA since May of 2011! So why use CIA as any excuse.....
Click to expand...

A couple reasons why Novo wins and Lilly helps in their defeat. 1. Novo out numbers Lilly reps. 2. Novo has a more aggressive selling style. 3. Lilly tries too hard wanting to please their doctors....what can I do to help you in your practice?....how can I serve you?....it's nauseating.
 












Anonymous said:
A couple reasons why Novo wins and Lilly helps in their defeat. 1. Novo out numbers Lilly reps. 2. Novo has a more aggressive selling style. 3. Lilly tries too hard wanting to please their doctors....what can I do to help you in your practice?....how can I serve you?....it's nauseating.
Click to expand...

4. Novo has better products. 5. Novo has been the world wide leader in Diabetes (Including the U. S.) for the last 15 years. 6. Novo has far better and more visionary senior leadership.
 












Anonymous said:
4. Novo has better products. 5. Novo has been the world wide leader in Diabetes (Including the U. S.) for the last 15 years. 6. Novo has far better and more visionary senior leadership.
Click to expand...

I disagree with number 4. The products are the same. Insulin is a commodity. You're fooling yourself if you think your product is any better than any other insulin. It's like saying..."my gold brick is better than your gold brick." When you think about it, it's a boring portfolio to sell.
 






Anonymous said:
A couple reasons why Novo wins and Lilly helps in their defeat. 1. Novo out numbers Lilly reps. 2. Novo has a more aggressive selling style. 3. Lilly tries too hard wanting to please their doctors....what can I do to help you in your practice?....how can I serve you?....it's nauseating.
Click to expand...


...and ironically, even with all the "Customer Value" Lilly hypes, Novo still commands more respect with doctors.
 






Anonymous said:
I disagree with number 4. The products are the same. Insulin is a commodity. You're fooling yourself if you think your product is any better than any other insulin. It's like saying..."my gold brick is better than your gold brick." When you think about it, it's a boring portfolio to sell.
Click to expand...

Funny, but true.
 


















Lilly diabetes has products that don't need professional salespeople. Lilly insulin sells itself. After all, insulin is a commodity. Of course they need a few administrative/sales folk to take orders in hospitals and other institutions. ( I should say that Novo and Sanofi are also in the same boat as Lilly.) Getting back to Lilly......they have a DPP4, and that is not a great drug...hell, it's a class of drug that shouldn't even be approved. Bottom line, Lilly has too many reps selling diabetes products (and I use the "selling" term lightly....very lightly), and I agree with earlier posts that the "chopping block" is in order. Lilly is a flower that bloomed years ago, and it is now dying.
 












Lilly never really understood what they had in their bag with Byetta (glp-1). Had they, the reps would have shown greater enthusiasm with Byetta, and not insulin. Lilly blew it when they turned their back on Amylin and went the way of the dpp4. They chose the lesser drug. Insulin sales will continue to decline, and glp-1 will continue to rise. Of course Lilly white Lilly has their own glp-1 coming out, and par for the course....it'll be too late. Your management fucked you guys. Lay-offs are coming you dopes.....especially for you stupid neuro reps who came over to the diabetes side. Your tenure and title will not save you.
 






Anonymous said:
Lilly never really understood what they had in their bag with Byetta (glp-1). Had they, the reps would have shown greater enthusiasm with Byetta, and not insulin. Lilly blew it when they turned their back on Amylin and went the way of the dpp4. They chose the lesser drug. Insulin sales will continue to decline, and glp-1 will continue to rise. Of course Lilly white Lilly has their own glp-1 coming out, and par for the course....it'll be too late. Your management fucked you guys. Lay-offs are coming you dopes.....especially for you stupid neuro reps who came over to the diabetes side. Your tenure and title will not save you.
Click to expand...

If you have kids you might last a little longer.

But yes amylin was right on, and I witnessed some colossal incompetence.
 






Anonymous said:
Lilly never really understood what they had in their bag with Byetta (glp-1). Had they, the reps would have shown greater enthusiasm with Byetta, and not insulin. Lilly blew it when they turned their back on Amylin and went the way of the dpp4. They chose the lesser drug. Insulin sales will continue to decline, and glp-1 will continue to rise. Of course Lilly white Lilly has their own glp-1 coming out, and par for the course....it'll be too late. Your management fucked you guys. Lay-offs are coming you dopes.....especially for you stupid neuro reps who came over to the diabetes side. Your tenure and title will not save you.
Click to expand...

Neuro reps are the best sales people we have- its funny when you leave neuro they almost always end up near the top or at the top of the rankings in other divisions...well known throughout upper management. Neuro will have priority in next realignment, followed by tenure and last 3 reviews.
 






Anonymous said:
Neuro reps are the best sales people we have- its funny when you leave neuro they almost always end up near the top or at the top of the rankings in other divisions...well known throughout upper management. Neuro will have priority in next realignment, followed by tenure and last 3 reviews.
Click to expand...

Keep dreaming neuro reps
 






Anonymous said:
Neuro reps are the best sales people we have- its funny when you leave neuro they almost always end up near the top or at the top of the rankings in other divisions...well known throughout upper management. Neuro will have priority in next realignment, followed by tenure and last 3 reviews.
Click to expand...

I have an old neuro rep who went into diabetes, and she is such a bloviator. She's a legend in her own mind....her top account does not like her.....she's not knowledgeable about her products or disease state....and all she wants to do is "service" her account. What a waste of money. She'll probably rank somewhere (hard not to with Lilly), and she'll continue with her stupid ways. She's hurting our business. The quote from above: "Neuro reps are the best sales people" is bullshit.
 






Top Bottom
Back
Quote